Singapore-based EUDA Health Holdings Limited (NASDAQ: EUDA) shared detailed information about the integrated cell therapy program planned under its latest non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. The program aims to distribute wellness and healthcare products and services in Asia, focusing on Singapore, Malaysia, and China. EUDA Health Holdings Limited specializes in third-party provided non-invasive solutions.